Viatris

VTRS · NASDAQ

$18.65+$0.39 (+2.14%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $18.26

VTRS analyst rating

BuyConsensus of 9 analysts over the last 12 months. 78% rate it a buy.

Strong buy0
Buy7
Hold2
Underperform0
Sell0

12-month price target · 13 analysts

Average $19.99 (+7.2% upside)

Low: $13.13
Now: $18.65
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

VTRS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 5, 2026	Maintains	Buy	$23.00 → $26.00	56%
Oppenheimer	Sep 23, 2026	Initiates	Outperform	$25.00	59%
Piper Sandler	Sep 16, 2026	Maintains	Neutral	$12.00 → $13.00	68%
Leerink Partners	Sep 9, 2026	Initiates	Outperform	$20.00	58%
Argus Research	Sep 8, 2026	Maintains	Buy	$15.00 → $20.00	51%
Barclays	May 19, 2026	Maintains	Overweight	$17.00 → $22.00	53%
JP Morgan	May 8, 2026	Maintains	Neutral	$17.00 → $18.00	65%
Truist Securities	May 8, 2026	Maintains	Buy	$18.00 → $20.00	51%
Barclays	Mar 24, 2026	Maintains	Overweight	$15.00 → $17.00	53%
Piper Sandler	Jan 28, 2026	Maintains	Neutral	$9.00 → $12.00	68%

The case for and against

Updated Oct 16, 2026

Bull case

Viatris is supported by a stabilizing core generics platform, with developed markets generics returning to growth in 1H26 and a sizable runway from the $175Bn of branded drug revenue coming off patent between 2025-2030, where the company targets roughly 70% participation. Its outlook is also strengthened by a mix shift toward more durable complex generics, including a goal of a ~35% increase in complex launches by 2030 and continued patch demand, with estradiol patch TRx growth of ~74% and Viatris share near ~42%. Additional upside comes from an improving pipeline and lifecycle assets, including fast-acting meloxicam and the women’s health patch portfolio, while selatogrel and cenerimod offer longer-dated optionality that could support growth and margins into the next decade.

Bear case

Viatris is burdened by a fragile growth profile because its outlook depends heavily on selatogrel, cenerimod, and fast-acting meloxicam, yet one program already missed its primary endpoint and the others face meaningful clinical, regulatory, and adoption risks. The company’s base business also looks vulnerable: the US generics mix shift may slow, APAC depends on regional CAGR targets, Greater China faces volume-based procurement, and JANZ is exposed to structural generic price reductions. With generics and biosimilars only one-third of sales and legacy products still central, persistent pricing and competition pressures could overwhelm margin expansion and make the core business a drag on growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.